Sponsors / KPTI
KPTI

Karyopharm Therapeutics Inc

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
11Trials in this database
21Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NCT02227251KPTIPhase 2Active not recruiting2026-12Estimated
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple MyelomaNCT03110562KPTIPhase 3Completed2020-02-18Actual
Maintenance With Selinexor/Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]NCT03555422KPTIPhase 3Completed2022-01-22Actual
A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.NCT04414475KPTIPhase 2Recruiting2028-01Estimated
A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNCT04442022KPTIPhase 2, Phase 3Active not recruiting2026-12Estimated
Study of Selinexor in Combination With Ruxolitinib in MyelofibrosisNCT04562389KPTIPhase 3Active not recruiting2026-02-20Actual
A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants With Previously Treated MyelofibrosisNCT04562870KPTIPhase 2Active not recruiting2026-09Estimated
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced MelanomaNCT04768881KPTIPhase 2Terminated2023-09-22Actual
A Study to Evaluate the Safety and Efficacy of Selinexor With or Without Pembrolizumab Versus Standard of Care in Previously Treated Metastatic Colorectal Cancer With RAS MutationsNCT04854434KPTIPhase 2Terminated2022-06-24Actual
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial CarcinomaNCT05611931KPTIPhase 3Active not recruiting2026-08Estimated
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate ThrombocytopeniaNCT05980806KPTIPhase 2Recruiting2027-06Estimated

Latest recorded trial changes

A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia

NCT05980806 · Karyopharm Therapeutics Inc

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Proportion of Participants with Spleen Volume Reduction 35 (SVR35) at Week 24.

+ After

Measure: Proportion of Participants with Spleen Volume Reduction ≥35% (SVR35) at Week 24

Planned enrollment decreased by 60 participants

− Before

118 participants (planned)

+ After

58 participants (planned)

Primary completion date changed

− Before

Apr 2026

+ After

Jun 2027

Check registry source
Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

NCT05611931 · Karyopharm Therapeutics Inc

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Progression Free Survival (PFS) Assessed by Investigator as per RECIST v1.1

+ After

Measure: Investigator assessed Progression Free Survival (PFS) per RECIST v1.1

Planned enrollment increased by 56 participants

− Before

220 participants (planned)

+ After

276 participants (planned)

Primary completion date changed

− Before

31 Jan 2025

+ After

Aug 2026

Check registry source
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis

NCT04562389 · Karyopharm Therapeutics Inc

· 4 fields changed

Participant count type changed

− Before

Estimated

+ After

Actual

Enrollment · participant count changed

− Before

350 participants (planned)

+ After

353 participants (actual)

Primary completion date changed

− Before

Sep 2025

+ After

Mar 2026

Recruitment status changed

− Before

Recruiting

+ After

Active not recruiting

Check registry source